Baseline characteristics of patients with newly diagnosed AML
| Characteristic . | Ivosidenib 500 mg, N = 34 . |
|---|---|
| Age, median (range), y | 76.5 (64-87) |
| Age category, n (%), y | |
| 60 to <75 | 15 (44) |
| ≥75 | 19 (56) |
| Women/men, n | 15/19 |
| ECOG PS at baseline, n (%) | |
| 0 | 8 (24) |
| 1 | 20 (59) |
| 2 | 5 (15) |
| 3 | 1 (3) |
| Nature of AML, n (%) | |
| De novo | 8 (24) |
| Secondary | |
| History of MDS | 18 (53) |
| History of MPD | 4 (12) |
| Treatment-related | 3 (9) |
| Other | 1 (3) |
| Prior hypomethylating agent, n (%) | 16 (47) |
| Cytogenetic risk status by investigator, n (%) | |
| Intermediate | 24 (71) |
| Poor | 9 (26) |
| Unknown | 1 (3) |
| Bone marrow blasts, median (range), % | 63 (1-97) |
| Hematology, n (%) | |
| White blood cells, ×109/L | |
| <15 | 28 (82) |
| 15 to <30 | 4 (12) |
| ≥30 | 2 (6) |
| Hemoglobin, g/L | |
| <80 | 5 (15) |
| ≥80 | 29 (85) |
| Platelets, ×109/L | |
| <50 | 21 (62) |
| ≥50 | 13 (38) |
| Transfusion dependent, n (%) | |
| Red blood cells | 16 (47) |
| Platelets | 14 (41) |
| Characteristic . | Ivosidenib 500 mg, N = 34 . |
|---|---|
| Age, median (range), y | 76.5 (64-87) |
| Age category, n (%), y | |
| 60 to <75 | 15 (44) |
| ≥75 | 19 (56) |
| Women/men, n | 15/19 |
| ECOG PS at baseline, n (%) | |
| 0 | 8 (24) |
| 1 | 20 (59) |
| 2 | 5 (15) |
| 3 | 1 (3) |
| Nature of AML, n (%) | |
| De novo | 8 (24) |
| Secondary | |
| History of MDS | 18 (53) |
| History of MPD | 4 (12) |
| Treatment-related | 3 (9) |
| Other | 1 (3) |
| Prior hypomethylating agent, n (%) | 16 (47) |
| Cytogenetic risk status by investigator, n (%) | |
| Intermediate | 24 (71) |
| Poor | 9 (26) |
| Unknown | 1 (3) |
| Bone marrow blasts, median (range), % | 63 (1-97) |
| Hematology, n (%) | |
| White blood cells, ×109/L | |
| <15 | 28 (82) |
| 15 to <30 | 4 (12) |
| ≥30 | 2 (6) |
| Hemoglobin, g/L | |
| <80 | 5 (15) |
| ≥80 | 29 (85) |
| Platelets, ×109/L | |
| <50 | 21 (62) |
| ≥50 | 13 (38) |
| Transfusion dependent, n (%) | |
| Red blood cells | 16 (47) |
| Platelets | 14 (41) |
MDS, myelodysplastic syndrome; MPD, myeloproliferative disease.